COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Magdalena plans to file IND for new psychoactive drug in 2025 for mental health, focusing on ADHD and schizophrenia. Potential paradigm shift in plant-based drug development -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena explores coca leaf's therapeutic benefits for ADHD and neuropsychiatric indications in partnership with Peru. Jaguar's Dr. King to present at Wisdom of the Leaf Coca Summit on coca-based Botanical Drugs -
-
-
COMMUNIQUÉ DE PRESSE
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Jaguar Health, Inc. initiates Phase 2 study for crofelemer, a novel plant-based drug, in pediatric MVID patients. Study aims to evaluate drug efficacy for rare diseases MVID and SBS-IF
